Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
46 - Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
Published online by Cambridge University Press: 03 March 2022
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
Summary
This chapter tells the story of one start-up biotech company that discovered and developed CT1812, a disease-modifying therapeutic for Alzheimer’s dieases that is currently in clinical trials. The company overcame significant financial and scientific challenges to discover and develop a drug candidate that works by a novel mechanism of action: CT1812 removes the toxic Aβ oligomers thought to cause AD from the site on brain cells where they create damage. The company went from an idea to five Phase 2 clinical trials. This case study will hopefully encourage other entrepreneurs to take this journey.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 513 - 523Publisher: Cambridge University PressPrint publication year: 2022